Literature DB >> 21744306

Virus-like particles for antigen delivery at mucosal surfaces.

K Schneider-Ohrum1, T M Ross.   

Abstract

Virus-like particles are a new type of vaccine platform that presents an attractive alternative to more traditional live-attenuated or inactivated/subunit vaccines. Virus-like particles (VLP) are composed of viral structural proteins that assemble spontaneously in cells, mimicking the live virus without the possibility of replication. They are readily recognized by the immune system, inducing both humoral and cellular immune responses. Here we review the development of VLP as vaccine delivery systems at mucosal surfaces. We first summarize the current status of VLP vaccines in general, and then discuss their use in mucosal vaccination approaches for several viruses that enter the host via the urogenital, respiratory or gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21744306     DOI: 10.1007/82_2011_135

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  14 in total

Review 1.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

2.  Expression and Purification of Virus-like Particles for Vaccination.

Authors:  Maria T Arevalo; Terianne M Wong; Ted M Ross
Journal:  J Vis Exp       Date:  2016-06-02       Impact factor: 1.355

3.  Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza.

Authors:  Dustin P Patterson; Agnieszka Rynda-Apple; Ann L Harmsen; Allen G Harmsen; Trevor Douglas
Journal:  ACS Nano       Date:  2013-04-10       Impact factor: 15.881

4.  Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model.

Authors:  Reagan G Cox; John J Erickson; Andrew K Hastings; Jennifer C Becker; Monika Johnson; Ryan E Craven; Sharon J Tollefson; Kelli L Boyd; John V Williams
Journal:  J Virol       Date:  2014-03-26       Impact factor: 5.103

5.  Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.

Authors:  Sujin Lee; Fu-Shi Quan; Youngman Kwon; Kaori Sakamoto; Sang-Moo Kang; Richard W Compans; Martin L Moore
Journal:  Antiviral Res       Date:  2014-09-18       Impact factor: 5.970

6.  A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2.

Authors:  Pierre-Louis Hervé; Mariam Raliou; Christiane Bourdieu; Catherine Dubuquoy; Agnès Petit-Camurdan; Nicolas Bertho; Jean-François Eléouët; Christophe Chevalier; Sabine Riffault
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

Review 7.  Virus-like particles as antigenic nanomaterials for inducing protective immune responses in the lung.

Authors:  Agnieszka Rynda-Apple; Dustin P Patterson; Trevor Douglas
Journal:  Nanomedicine (Lond)       Date:  2014       Impact factor: 5.307

8.  Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.

Authors:  Vladimir Beljanski; Cindy Chiang; Greg A Kirchenbaum; David Olagnier; Chalise E Bloom; Terianne Wong; Elias K Haddad; Lydie Trautmann; Ted M Ross; John Hiscott
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

9.  A Single Intramuscular Dose of a Plant-Made Virus-Like Particle Vaccine Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Virus Challenge despite a Modest/Absent Humoral Response.

Authors:  Breanna Hodgins; Karen K Yam; Kaitlin Winter; Stephane Pillet; Nathalie Landry; Brian J Ward
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

10.  Hepatitis B virus core antigen as a carrier for Chlamydia trachomatis MOMP multi-epitope peptide enhances protection against genital chlamydial infection.

Authors:  Pengfei Jiang; Wangqi Du; Yirong Xiong; Yan Lv; Juan Feng; Shanli Zhu; Xiangyang Xue; Shao Chen; Lifang Zhang
Journal:  Oncotarget       Date:  2015-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.